Alatrofloxacin

CH4O3S 75-75-2) see Alatrofloxacin mesilate Alendronate sodium Dolasetron mesilate Glaziovine Nelfinavir mesylate Tirilazad mesilate Trovafloxacin mesilate... 

Hall, I. H., Schwab, U. E., Ward, E. S., and Ives, T. J. Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomod-ulation events of human THP-1 monocytes. Biomed. Pharmacother. 57(8) 359—365, 2003. 

Alatrofloxacin is a fluoronaphthyridone that is hydrolysed to the active moiety, trovafloxacin, after intravenous administration. This fourth-generation broad-spectrum fluoroquinolone has activity against Gram-positive, Gram-negative, anerobic, and atypical respiratory pathogens. Because it has significant hepato-toxicity, the list of appropriate indications for trovafloxacin has been restricted. 

A 37-year-old Asian man received several antibiotics (including intravenous ceftazidime, gentamicin, merope-nem, metronidazole, and vancomycin) postoperatively. After 3 weeks he was given alatrofloxacin 75 mg in 25 ml of dextrose 5% (1.875 mg/ml) and developed generalized clonus. On rechallenge, infusing at half the initial rate, the seizure recurred. A CT scan of the brain was normal. 

Seizures are rare but have occurred during treatment with other fluoroquinolones. This is the first report of a case of seizures associated with slow infusion of alatrofloxacin. However, as of 21 June 2000, the manufacturers had received 53 reports of seizures through worldwide postmarketing surveillance. In rat hippocampus slices, trovafloxacin had significant convulsive potential the underlying mechanism is hitherto incompletely understood. 

Alatrofloxacin has been associated with severe leukopenia (7). 

A 79-year-old white man was treated with intravenous alatrofloxacin mesylate 200 mg bd for 5 days. His... 

---